Heterogeneity of Loss Aversion in Pathological Gambling

被引:25
|
作者
Takeuchi, Hideaki [1 ]
Kawada, Ryosaku [1 ]
Tsurumi, Kosuke [1 ]
Yokoyama, Naoto [1 ]
Takemura, Ariyoshi [1 ]
Murao, Takuro [1 ]
Murai, Toshiya [1 ]
Takahashi, Hidehiko [1 ]
机构
[1] Kyoto Univ, Grad Sch Med, Dept Psychiat, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan
基金
日本学术振兴会;
关键词
Behavioral economics; Heterogeneity; Loss aversion; Pathological gambling; Personality traits; DOUBLE-BLIND; PROSPECT-THEORY; IMPULSIVITY; PAROXETINE; GAMBLERS; DECISION;
D O I
10.1007/s10899-015-9587-1
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Pathological gambling (PG) is characterized by continual repeated gambling behavior despite negative consequences. PG is considered to be a disorder of altered decision-making under risk, and behavioral economics tools were utilized by studies on decision-making under risk. At the same time, PG was suggested to be a heterogeneous disorder in terms of personality traits as well as risk attitude. We aimed to examine the heterogeneity of PG in terms of loss aversion, which means that a loss is subjectively felt to be larger than the same amount of gain. Thirty-one male PG subjects and 26 male healthy control (HC) subjects underwent a behavioral economics task for estimation of loss aversion and personality traits assessment. Although loss aversion in PG subjects was not significantly different from that in HC subjects, distributions of loss aversion differed between PG and HC subjects. HC subjects were uniformly classified into three levels (low, middle, high) of loss aversion, whereas PG subjects were mostly classified into the two extremes, and few PG subjects were classified into the middle range. PG subjects with low and high loss aversion showed a significant difference in anxiety, excitement-seeking and craving intensity. Our study suggested that PG was a heterogeneous disorder in terms of loss aversion. This result might be useful for understanding cognitive and neurobiological mechanisms and the establishment of treatment strategies for PG.
引用
收藏
页码:1143 / 1154
页数:12
相关论文
共 50 条
  • [1] Heterogeneity of Loss Aversion in Pathological Gambling
    Hideaki Takeuchi
    Ryosaku Kawada
    Kosuke Tsurumi
    Naoto Yokoyama
    Ariyoshi Takemura
    Takuro Murao
    Toshiya Murai
    Hidehiko Takahashi
    Journal of Gambling Studies, 2016, 32 : 1143 - 1154
  • [2] Enhanced Risk Aversion, But Not Loss Aversion, in Unmedicated Pathological Anxiety
    Charpentier, Caroline J.
    Aylward, Jessica
    Roiser, Jonathan P.
    Robinson, Oliver J.
    BIOLOGICAL PSYCHIATRY, 2017, 81 (12) : 1014 - 1022
  • [3] Gambling versus investment: Lay theory and loss aversion
    Shang, Xuesong
    Duan, Hebing
    Lu, Jingyi
    JOURNAL OF ECONOMIC PSYCHOLOGY, 2021, 84
  • [4] Pathological gambling and impulsivity: an Italian study
    Marazziti, Donatella
    Picchetti, Michela
    Baroni, Stefano
    Consoli, Giorgio
    Ceresoli, Diana
    Massimetti, Gabriele
    Dell'Osso, Mario Catena
    RIVISTA DI PSICHIATRIA, 2014, 49 (02) : 95 - 99
  • [5] Reduced loss aversion in pathological gambling and alcohol dependence is associated with differential alterations in amygdala and prefrontal functioning
    Genauck, Alexander
    Quester, Saskia
    Wuestenberg, Torsten
    Moersen, Chantal
    Heinz, Andreas
    Romanczuk-Seiferth, Nina
    SCIENTIFIC REPORTS, 2017, 7
  • [6] A behavioral definition of loss aversion
    Blavatskyy, Pavlo R.
    ECONOMICS LETTERS, 2024, 235
  • [7] Treatment of pathological gambling
    Leung, Kit Sang
    Cottler, Linda B.
    CURRENT OPINION IN PSYCHIATRY, 2009, 22 (01) : 69 - 74
  • [8] Loss aversion
    Blavatskyy, Pavlo R.
    ECONOMIC THEORY, 2011, 46 (01) : 127 - 148
  • [9] Psychological Heterogeneity in a Queue: The Impact of Loss Aversion on Service Pricing
    Jiang Tao
    Gao Li
    Chai Xudong
    Bu Qihui
    JOURNAL OF SYSTEMS SCIENCE & COMPLEXITY, 2023, 36 (06) : 2536 - 2558
  • [10] Pharmacological treatments in pathological gambling
    Grant, Jon E.
    Odlaug, Brian L.
    Schreiber, Liana R. N.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 77 (02) : 375 - 381